“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
HOME > ORGANIZATION
ORGANIZATION
- JPWA Vice President Ken Suzuki Expected to Lead JPWA After President Bessho’s Term Ends in May
March 22, 2013
- EFPIA Simulation: New Drug Market Up Mere 0.4 Trillion Yen by 2022 Even with Premium
March 19, 2013
- Transparency Guidelines: JPMA Proposes One-Year Hold on Disclosure of Individual Payments
March 18, 2013
- Japan Society of Generic Medicines Calls for 80% Generic Drug Share by Volume within 5 Years
March 8, 2013
- JPMA Issues Statement Calling for IP Protection, Expresses Concerns over Issuance of Compulsory Licenses
March 7, 2013
- Generic Market Share at 26.1% on Volume Basis in 3rd Quarter FY2012: JGA
March 6, 2013
- Relationships with Doctors Unchanged after Stricter Rules on Entertainment: Maker FTC Survey
February 27, 2013
- Yakukeiren’s Direct Joint Purchasing System for Generic Drugs to Go into Full Operation in FY2013
February 27, 2013
- TPP Hoped to Set Standard for Global IP Protection Rules: PhRMA Japan Rep. Wolf
February 25, 2013
- JPMA’s Nakatani Says Transparency Guidelines Will Go into Force in April as Planned
February 25, 2013
- JPMA’s New Code of Practice to Take Effect in April; Transparency in Relations with Wholesalers to Be One Focus
February 22, 2013
- Osaka-Based NPO to Take on Outsourcing of GMP Compliance Audit on Drug Substance Makers
February 21, 2013
- Pharmaceutical Trade Deficit “Not Directly Related to Global Competitiveness” of Domestic Industry: Mr Nagasawa of OPIR
February 20, 2013
- JMA to Host WMA Expert Conference on Revision of Helsinki Declaration in Tokyo on Feb. 28
February 20, 2013
- Biotech Association Asks MHLW to Include Drugs for Intractable Diseases and Orphan Drugs in Early Approval System
February 18, 2013
- JMA President Yokokura Opposes TPP Agreement, Expressing Concerns over Intervention in NHI Pricing
February 15, 2013
- PPTA President Airs Concern over Japanese Govt Intervention in Price Setting of Blood Products
February 13, 2013
- RAD-AR Council to Set Guidelines for Information Provisioning on Ethical Drugs
February 12, 2013
- JMA Exec. Mikami Wants a Hold on Info Disclosures Based on Transparency Guidelines
February 8, 2013
- Permanent Introduction of Premium for New Drug Development One of PhRMA’s “Priorities in 2013”: Japan Chair
February 5, 2013
ページ
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…